Natera, Inc. (NTRA) Earns Buy Rating from Canaccord Genuity
Natera, Inc. (NASDAQ:NTRA)‘s stock had its “buy” rating reaffirmed by analysts at Canaccord Genuity in a research note issued on Tuesday. They currently have a $15.00 target price on the medical research company’s stock. Canaccord Genuity’s price target points to a potential upside of 60.60% from the company’s previous close.
NTRA has been the topic of a number of other reports. ValuEngine lowered shares of Natera from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Cowen and Company reiterated a “buy” rating and set a $14.00 price target on shares of Natera in a research note on Friday, September 1st. Robert W. Baird reiterated a “buy” rating on shares of Natera in a research note on Tuesday, October 24th. Zacks Investment Research lowered shares of Natera from a “buy” rating to a “sell” rating in a research note on Saturday, August 12th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $16.00 price target (up from $13.00) on shares of Natera in a research note on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $15.00.
Shares of Natera (NASDAQ:NTRA) traded up $0.15 on Tuesday, reaching $9.34. 128,900 shares of the company traded hands, compared to its average volume of 199,823. Natera has a 12-month low of $7.35 and a 12-month high of $14.76. The company has a debt-to-equity ratio of 2.43, a quick ratio of 1.75 and a current ratio of 1.85.
Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $56.66 million during the quarter, compared to analysts’ expectations of $55.31 million. Natera had a negative net margin of 62.34% and a negative return on equity of 197.09%. The firm’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.50) earnings per share. analysts expect that Natera will post -2.12 earnings per share for the current year.
In other news, insider Jonathan Sheena sold 120,000 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $12.54, for a total transaction of $1,504,800.00. Following the completion of the transaction, the insider now directly owns 533,208 shares of the company’s stock, valued at $6,686,428.32. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 12.57% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. Capital World Investors grew its position in shares of Natera by 0.8% during the second quarter. Capital World Investors now owns 4,222,609 shares of the medical research company’s stock worth $45,858,000 after buying an additional 32,000 shares in the last quarter. Jennison Associates LLC grew its position in shares of Natera by 1.0% during the second quarter. Jennison Associates LLC now owns 2,356,346 shares of the medical research company’s stock worth $25,590,000 after buying an additional 23,473 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Natera by 12.6% during the second quarter. Vanguard Group Inc. now owns 2,261,052 shares of the medical research company’s stock worth $24,555,000 after buying an additional 253,344 shares in the last quarter. Macquarie Group Ltd. grew its position in shares of Natera by 25.9% during the third quarter. Macquarie Group Ltd. now owns 1,336,993 shares of the medical research company’s stock worth $17,234,000 after buying an additional 275,113 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Natera by 1.5% during the second quarter. Bank of New York Mellon Corp now owns 634,743 shares of the medical research company’s stock worth $6,893,000 after buying an additional 9,223 shares in the last quarter. 60.54% of the stock is owned by institutional investors and hedge funds.
Natera Company Profile
Receive News & Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.